What MAT Is
Three FDA-approved medications for opioid use disorder: buprenorphine (Suboxone, Sublocade), methadone (administered through licensed clinics), and naltrexone (Vivitrol injection). For alcohol use disorder: naltrexone (oral or injection), acamprosate, and disulfiram. MAT is evidence-based, endorsed by SAMHSA, ASAM, and NIDA. It's not 'replacing one addiction with another' — at therapeutic doses, buprenorphine stabilizes brain chemistry without producing euphoria.
MAT During Inpatient Stays
The programs we refer to integrate MAT throughout the continuum: induction during detox, maintenance during residential, and continuation through outpatient aftercare. Not all programs do this — some are abstinence-only and discharge patients off medication. Our placement advisors match you with the right approach for your situation.
MAT and Insurance
Under NJ A2031/S1339 and the federal MHPAEA, MAT medications must be covered on par with medications for other chronic conditions. AmeriHealth NJ expanded MAT coverage in 2025 to include methadone, buprenorphine, and naltrexone. Most NJ PPO plans cover MAT without prior authorization in the inpatient setting.